U.S. Healthtech Stock News

NovoCure (NVCR) just made a meaningful leadership shift, with CEO and director Ashley Cordova stepping down and long time insider Frank Leonard stepping up to the top job, a move investors will be parsing carefully. See our latest analysis for NovoCure. The leadership shake up lands as the share price, now at $13.66, has bounced with a 7 day share price return of 16.16 percent. It still carries a bruising 1 year total shareholder return of around negative 55 percent, signaling improving short...

Fulton Financial (FULT) has quietly put up a solid run lately, with the stock gaining about 5% this week and roughly 12% over the past month, outpacing many regional bank peers. See our latest analysis for Fulton Financial. Zooming out, that recent strength sits on top of a more measured backdrop. The share price is now at $19.96, with a modest year to date share price return but a solid five year total shareholder return that signals momentum has been building over the long haul. If Fulton’s...

Amazon.com (AMZN) is leaning hard into its next growth engine, committing $35 billion to India through 2030 to build out AI capabilities, logistics, and exports in what it sees as a long runway market. See our latest analysis for Amazon.com. Even with the latest share price at $230.28 and a relatively modest year to date share price return of 4.57%, the three year total shareholder return of 160.35% shows investors are still backing Amazon’s long term AI and cloud story, even if momentum has...

Broadridge Financial Solutions (BR) has been quietly reshaping its fintech toolkit, from migrating its Shareholder Disclosure Hub to Amazon Web Services to partnering with Xceptor and naming a new head of strategy for its broker dealer arm. See our latest analysis for Broadridge Financial Solutions. The latest fintech upgrades and strategy hires come as Broadridge’s $231.5 share price reflects a mixed picture, with a modestly positive year to date share price return and a much stronger three...

If you are wondering whether Atlassian is a bargain or a value trap at today’s price, you are not alone. This breakdown is designed to help you decide with greater confidence. The stock has bounced about 4.3% over the last week and 3.6% in the past month, but it is still down roughly 32.6% year to date and 41.5% over the last year. That combination often signals either deep value or lingering risk. Those moves have come as investors weigh Atlassian’s ongoing push to scale its cloud platform...

While Groupon, Inc. ( NASDAQ:GRPN ) shareholders are probably generally happy, the stock hasn't had particularly good...

Over the past year, insiders sold US$424k worth of Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) stock at an average...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Patrick Industries recently appeared in Mairs & Power Small Cap Fund’s third-quarter 2025 investor letter as a new holding, and earlier this month presented at the Raymond James TMT & Consumer Conference in New York, underscoring its profile across recreational vehicle, marine, manufactured housing, and residential construction markets. The fund’s decision to initiate a position after tariff and inventory concerns had pressured the stock highlights how some institutional investors view...

ICF International (ICFI) has been grinding through a mixed stretch in the market, and that uneven share performance is nudging investors to revisit whether the current valuation still makes sense. See our latest analysis for ICF International. Over the past few months, ICF International’s share price has tried to claw back ground, with a 1 month share price return of 11.12 percent partially offsetting a weaker year to date share price return of 24.44 percent and a 1 year total shareholder...

Pinnacle Financial Partners (PNFP) has quietly outperformed many regional peers, with the stock up about 6% this week and roughly 16% over the past month, drawing fresh attention to its valuation. See our latest analysis for Pinnacle Financial Partners. Zooming out, that short burst of strength comes after a tougher stretch, with the share price still showing a negative year to date share price return, while the five year total shareholder return near 70% hints at longer term compounding and...

CVS Health (CVS) just reset the bar for its turnaround, lifting its 2025 and 2026 guidance and laying out mid teens earnings growth targets through 2028 while unveiling an AI native consumer engagement platform. See our latest analysis for CVS Health. The updated guidance and AI platform plans have clearly caught investors’ attention. CVS Health’s 1 day share price return of 2.36% adds to an 82.79% year to date share price return and a 70% 1 year total shareholder return, suggesting momentum...

Palantir Technologies (PLTR) keeps drawing attention as its share price continues to swing after a huge run this year, prompting investors to revisit what is actually driving the story at current levels. See our latest analysis for Palantir Technologies. After a blistering run this year, Palantir’s latest share price of $187.54 reflects a market that is pausing to reassess expectations. This comes even as its year to date share price return of 149.42 percent and three year total shareholder...

Earlier this month, BrightSpring Health Services presented at the Bank of America Home Care Conference, where CEO Jon B. Rousseau and CFO Jennifer A. Phipps outlined the company’s home- and community-based care platform to investors. Shortly afterward, William Blair initiated research coverage on BrightSpring with a positive rating, signaling increased institutional attention and interest in the company’s long-term business outlook. Now, we’ll examine how William Blair’s new coverage and...

If you are wondering whether Nordson is a quietly overvalued industrial name or a sleeper opportunity hiding in plain sight, this breakdown will walk you through what the current price is really implying. The stock has drifted slightly lower in the short term, down 1.7% over the last week and 0.8% over the last month, but it is still up 14.4% year to date and 25.5% over five years. This hints at a longer term wealth compounder with some recent cooling. Recent coverage has focused on...

Triumph Financial (TFIN) just added BlueGrace Logistics to its Triumph Network, a client win that underscores how its payments and automation platform is gaining traction with larger freight players and recurring transaction volumes. See our latest analysis for Triumph Financial. The BlueGrace win lands at a time when Triumph’s 1 month share price return of 14.82 percent contrasts sharply with a negative year to date share price return, while a 3 year total shareholder return of 27.47 percent...

If you have been wondering whether Celanese is a beaten down bargain or a value trap, this is exactly the kind of setup where a deeper valuation check can make a real difference to your returns. The stock has bounced 7.4% over the last week and 3.4% over the last month, but that is off a much lower base after a painful slide of around 37.5% year to date and 37.7% over the last year. Investors have been digesting a mix of macro headlines around demand for specialty materials and chemicals,...

Proto Labs (PRLB) has quietly put together a strong run this year, with the stock up about 37% year to date and roughly 20% over the past year, outpacing many industrial peers. See our latest analysis for Proto Labs. That momentum has not come out of nowhere, with a 7.5% 1 month share price return and a 20.2% 1 year total shareholder return suggesting investors are steadily warming to Proto Labs growth and risk profile. If Proto Labs has you rethinking your watchlist, this is a good moment to...

Samsara Inc. recently reported its third-quarter 2026 results, with revenue rising to US$415.98 million and net income reaching US$7.77 million, marking its first quarter of GAAP profitability after a loss in the prior year period. The company paired this milestone with a 29% year-on-year increase in Annual Recurring Revenue, record additions of large enterprise customers, and growing international traction, underscored by customer case studies such as Swissport’s incident and vehicle damage...

Earlier this month, Equifax launched Income Qualify, a tool that uses verified income and employment data from The Work Number to help mortgage lenders assess borrowers earlier in the prequalification and pre-approval process. By pairing Equifax credit files with upfront income verification and offering lower-priced VantageScore mortgage scores, the company is pushing deeper into lenders’ workflow and cost decisions. We’ll now examine how earlier access to verified income data for mortgage...

Brookfield Infrastructure Partners (NYSE:BIP) just renewed its normal course issuer bids, giving management fresh approval to buy back and cancel a meaningful slice of LP units, preferred units, and exchangeable shares over the next year. See our latest analysis for Brookfield Infrastructure Partners. The timing of these renewed buybacks lines up with a clear turn in sentiment. The latest share price of $35.10 and a solid 90 day share price return of 14.48% support a 10.76% one year total...

Wondering if iQIYI at around $2 a share is a hidden bargain or a value trap? You are not alone, and this is exactly what we are going to unpack. The stock is roughly flat over the last week, down 8.1% over the past month and about 11% over the last year, after a brutal 88.2% slide over five years that still shapes how the market views its risk and recovery potential. Recent headlines have centered on iQIYI's ongoing push into premium originals and partnerships in China as it tries to...

If you are wondering whether Turning Point Brands is still a smart buy after its big run up, you are not alone. This article is going to unpack exactly what the current price might be baking in. The stock has climbed 6.0% over the last week, 4.1% over the last month, and is now up an eye catching 72.5% year to date, with a massive 430.9% gain over three years and 151.2% over five years that has clearly changed how the market views its prospects. Recent attention around Turning Point Brands...

Crinetics Pharmaceuticals (CRNX) just hit an important milestone, as it has dosed the first patient in its Phase 1/2 BRAVESST2 trial of CRN09682 for SST2 positive neuroendocrine tumors and other SST2 expressing solid tumors. See our latest analysis for Crinetics Pharmaceuticals. The BRAVESST2 milestone comes after a powerful run in the share price, with a roughly 45% 3 month share price return helping claw back some of the softer year to date move and setting up stronger long term momentum...